We have already described an in vitro patch test performed on reconstructed human epidermis using multiple endpoint analysis including cell viability (MTT reduction), histology, and IL-1a release (Tornier et al., 2006). Here, we examined the possibility of using non-invasive methods as endpoints for tissue traceability reasons as well as for reducing costs since both histology and viability assays could now be realized on the same tissues. We thus performed resazurin reduction, LDH release and glucose consumption as cell viability assays. Moreover, we also studied our new endpoints after a 24 or 72h post-incubation.